At Ayala, we are dedicated to developing targeted therapies specifically for patients living with rare and aggressive diseases. In combination with next-generation sequencing and our proprietary bioinformatics platform, we are pioneering a novel approach to cancer treatment.
February 20, 2024
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
February 06, 2024
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals